Chang, Y.-S.; Su, C.-W.; Chen, S.-C.; Chen, Y.-Y.; Liang, Y.-J.; Wu, J.-C.
Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. Cells 2022, 11, 634.
https://doi.org/10.3390/cells11040634
AMA Style
Chang Y-S, Su C-W, Chen S-C, Chen Y-Y, Liang Y-J, Wu J-C.
Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. Cells. 2022; 11(4):634.
https://doi.org/10.3390/cells11040634
Chicago/Turabian Style
Chang, Yung-Sheng, Chien-Wei Su, San-Chi Chen, Yen-Ying Chen, Yuh-Jin Liang, and Jaw-Ching Wu.
2022. "Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance" Cells 11, no. 4: 634.
https://doi.org/10.3390/cells11040634
APA Style
Chang, Y.-S., Su, C.-W., Chen, S.-C., Chen, Y.-Y., Liang, Y.-J., & Wu, J.-C.
(2022). Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. Cells, 11(4), 634.
https://doi.org/10.3390/cells11040634